Mycobacterium avium complex infection in HIV/AIDS patients

References

• Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Resp. Crit. Care. Med.175(4), 367–416 (2007).
   PubMed Web of Science ®Google Scholar
• Horsburgh CR, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am. Rev. Respir. Dis.139(1), 4–7 (1989).
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am. Rev. Respir. Dis.146(2), 285–289 (1992).
   PubMed Web of Science ®Google Scholar
• Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin. Infect. Dis.15(1), 161–162 (1992).
   PubMed Web of Science ®Google Scholar
• Kirschner, RA, Parker BC, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of the southeastern United States and their association with environmental variables. Am. Rev. Respir. Dis.145(2), 271–275 (1993).
   Google Scholar
• Horsburgh CR Jr. Epidemiology of Mycobacterium avium complex. In: Mycobacterium avium complex infection: Progress in Research and Treatment. Korvick JA, Benson CA (Eds). Marcel Dekker, NY, USA 1–22 (1996).
   Google Scholar
• Carter G, Wu M, Drummond DC, Bermudez LE. Characterization of biofilm formation by clinical isolates of Mycobacterium avium. J. Med. Microbiol.52(9), 747–752 (2003).
   PubMed Web of Science ®Google Scholar
• Primm TP, Lucero CA, Falkinham JO. Health impacts of environmental Mycobacteria. Clin. Microbiol. Rev.106(17), 98–106 (2004).
   Google Scholar
• Norton CD, Le Chevallier MW, Falkinham JO. Survival of Mycobacterium avium in a model distribution system. Water Res.38(6), 1457–1466 (2004).
   PubMed Web of Science ®Google Scholar
• von Reyn CF, Maslow JN, Barber TW, Falkinham JO, Arbeit RD. Persistent colonization of potable water as a source of Mycobacterium avium infection in AIDS. Lancet343(8906), 1137–1141 (1994).
   PubMed Web of Science ®Google Scholar
• Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin. Infect. Dis.20(4), 954–963 (1995).
   PubMed Web of Science ®Google Scholar
• von Reyn CF, Waddell RD, Eaton T et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J. Clin. Microbiol.31(12), 3227–3230 (1993).
   PubMed Web of Science ®Google Scholar
• George KL, Falkinham JO. Selective medium for the isolation and enumeration of Mycobacterium avium-intracellulare and M. scrofulaceum. Can. J. Microbiol.32(1), 10–14 (1986).
   PubMed Web of Science ®Google Scholar
• Cirillo JD, Falkow S, Tompkins LS, Bermudez LE. Interaction of. Mycobacterium avium with environmental amoebae enhances virulence. Infect. Immun.65(9), 3759–3467 (1997).
   PubMed Web of Science ®Google Scholar
• Kaur D, Berg S, Dinadayala P et al. Biosynthesis of mycobacterial lipoarabinomannan: role of a branching mannosyltransferase. Proc. Natl Acad. Sci. USA103(37), 13664–13669 (2006).
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob. Agents Chemother.34(5), 759–764 (1990).
   PubMed Web of Science ®Google Scholar
• Hoffner SE, Svenson SB, Beezer AE. Microcalorimetric studies of the initial interaction between antimycobacterial drugs and Mycobacterium avium. J. Antimicrob. Chemother.25(3), 353–359 (1990).
   PubMed Web of Science ®Google Scholar
• Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990’s. Clin. Microbiol. Rev.16(2), 319–354 (2003).
   PubMed Web of Science ®Google Scholar
• Georgiev VS. Opportunistic Infections Treatment and Prophylaxis. Humana Press, NJ, USA 96 (2003).
   Google Scholar
• Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium–intracellulare complex bacteriemia in human immunodeficiency virus-positive patients. J. Infect. Dis.165(6), 1082–1085 (1992).
   PubMed Web of Science ®Google Scholar
• Turenne CY, Semret M, Cousins DV, Collins DM, Behr MA. Sequencing of hsp65 distinguishes among subsets of the Mycobacterium avium complex. J. Clin. Microbiol.44(2), 433–440 (2006).
   PubMed Web of Science ®Google Scholar
• Sangari FJ, Goodman J, Petrofsky M, Kolonoski P, Bermudez LE. Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes. Infect. Immun.69, 1515–1520 (2001).
   PubMed Web of Science ®Google Scholar
• Chin DP, Hopewell P, Stone EN et al. Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. J. Infect. Dis.169(2), 289–295 (1994).
   PubMed Web of Science ®Google Scholar
• Champsi J, Young LS, Bermudez LE. Production of TNF-α, IL-6 and TGF-β, and expression of receptors for TNF-α and IL-6, during murine Mycobacterium avium infection. Immunology84(4), 549–554 (1995).
   PubMed Web of Science ®Google Scholar
• McGregor RR, Hafner R, Wu JW et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res. Hum. Retroviruses21(8), 689–695 (2005).
   PubMed Web of Science ®Google Scholar
• Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev.11(4), 321 (2000).
   PubMed Web of Science ®Google Scholar
• Naik E, Le Blanc S, Tang J, Jacobson LP, Kaslow RA. The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-seropositive whites. J. Acquir. Immune Defic. Syndr.33(2), 140–145 (2003).
   PubMed Web of Science ®Google Scholar
• Vázquez N, Greenwell-Wild T, Rekka S, Orenstein JM, Wahl SM. Mycobacterium avium-induced SOCS contributes to resistance to IFN-γ-mediated mycobactericidal activity in human macrophages. J. Leukoc. Biol.80(5), 1136–1144 (2006).
   PubMed Web of Science ®Google Scholar
• Greenberg SS, Xie J, Kolls J, Mason C, Didier P. Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of Mycobacterium tuberculosis and Mycobacterium avium. Proc. Soc. Exp. Biol. Med.209(1), 46–53 (1995).
   PubMed Web of Science ®Google Scholar
• Mohgheghpour N, Gammon D, van Vollenhoven A, Hornig Y, Bermudez LE, Young LS. Mycobacterium avium reduces expression of costimulatory/adhesion molecules by human monocytes. Cell. Immunol.176(1), 82–91 (1997).
   PubMed Web of Science ®Google Scholar
• Petrofsky M, Bermudez LE. CD4+ T cells but not CD8+ or γδ+ lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route. Infect. Immun.7(5), 2621–2627 (2005).
   Google Scholar
• Ghassemi M, Novak RM, Khalili MF, Zhou J. Viable Mycobacterium avium is required for the majority of human immunodeficiency virus-induced upregulation in monocytoid cells. J. Med. Microbiol.52(10), 877–882 (2003).
   PubMed Web of Science ®Google Scholar
• Lazaro E, Coureau G, Guedj J et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir. Ther.11(3), 343–350 (2006).
   PubMed Web of Science ®Google Scholar
• Podlekareva D, Mocroft A, Dragsted UB et al. Factors associated with the development of OI in HIV-infected adults with high CD4+ cell counts: a EuroSIDA study. J. Infect. Dis.194(5), 633–641 (2006).
   PubMed Web of Science ®Google Scholar
• French M, Keane N, McKinnon E, Phung S, Price P. Susceptibility to OI in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells. HIV Med.8(3), 148–155 (2007).
   PubMed Web of Science ®Google Scholar
• Tomioka H. Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des.10(26), 3297–3312 (2004).
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials.5(2), 80–85 (2004).
   PubMed Web of Science ®Google Scholar
• de Silva TI, Cope A, Goepel J, Greig JM. The use of adjuvant granulocyte–macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection. J. Infect.54(4), 207–210 (2007).
   PubMed Web of Science ®Google Scholar
• Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial pulmonary diseases and an assessment of the value of immunotherapy with M. vaccae: a pragmatic, randomised trial by The British Thoracic Society. Thorax (2008) (Epub ahead of print).
   Google Scholar
• Horsburgh CR Jr. The pathophysiology of disseminated Mycobacterium avium disease in AIDS. J. Infect. Dis.179(Suppl. 3), S461–S465 (1999).
   PubMedGoogle Scholar
• Barbaro DJ, Orcutt VL, Coldiron BM. Mycobacterium avium–Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Rev. Infect. Dis.11(4), 625–628 (1989).
   PubMedGoogle Scholar
• Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin. Infect. Dis.18(Suppl.), 218–222 (1994).
   PubMedGoogle Scholar
• Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J. Infect. Dis.170(6), 1601–1605 (1994).
   PubMed Web of Science ®Google Scholar
• Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin. Microbiol. Rev.6(3), 266–310 (1993).
   PubMed Web of Science ®Google Scholar
• Gordin FM, Cohn DL, Sullam PM, Schoenfelder JR, Wynne BA, Horsburgh CR Jr. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J. Infect. Dis.176(1), 126–132 (1997).
   PubMed Web of Science ®Google Scholar
• Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin. Infect. Dis.17(1), 7–20 (1993).
   PubMed Web of Science ®Google Scholar
• Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE 3rd. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J. Infect. Dis.165(3), 577–580 (1992).
   PubMed Web of Science ®Google Scholar
• Karakousis PC, Moore RD, Chaisson RE. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet4(9), 557–565 (2004).
   Web of Science ®Google Scholar
• Kuitert LM, Thomas MG, Ellis-Pegler RB. Outcome of untreated Mycobacterium avium–intracellulare complex infection in AIDS. AIDS5(8), 1036–1038 (1991).
   PubMed Web of Science ®Google Scholar
• Modilevsky T, Sattler FR, Barnes PF. Mycobacterial disease in patients with human immunodeficiency virus infection. Arch. Intern. Med.149(10), 2201–2205 (1989).
   PubMedGoogle Scholar
• Helbert M, Robinson D, Buchanan D et al. Mycobacterial infection in patients infected with the human immunodeficiency virus. Thorax45(11), 45–48 (1990).
   PubMed Web of Science ®Google Scholar
• Damsker B, Bottone EJ. Mycobacterium avium–Mycobacterium intracellulare from the intestinal tracts of patients with acquired immunodeficiency syndrome: concepts regarding acquisition and pathogenesis. J. Infect. Dis.151(1), 179–181 (1985).
   PubMed Web of Science ®Google Scholar
• Gadkowski LB, Stout JE. Current challenges in diagnosing and treating nontuberculous mycobacterial pulmonary disease. Infect. Med.23, 425–433 (2006).
   Google Scholar
• Falkinham III JO. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev.9(2), 177–245 (1996).
   PubMed Web of Science ®Google Scholar
• Havlir D, Kemper CA, Deresinski S. Reproducibility of lysis-centrifugation cultures for quantification of Mycobacterium avium complex bacteremia. J. Clin. Microbiol.31(7), 1794–1798 (1993).
   PubMed Web of Science ®Google Scholar
• Hellyer TJ, Brown IN, Taylor MB, Allen BW, Easmon CS. Gastrointestinal involvement in Mycobacterium avium–intracellulare infection of patients with HIV. J. Infect.26(1), 55–66 (1993).
   PubMed Web of Science ®Google Scholar
• Pantongrag-Brown L, Krebs TL, Daly BD et al. Frequency of abdominal CT findings in AIDS patients with M. avium complex bacteraemia. Clin. Radiol.53(11), 816–819 (1998).
   PubMed Web of Science ®Google Scholar
• Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium avium intracellulare from blood of patients with AIDS. J. Clin. Pathol.41(6), 687–690 (1988).
   PubMed Web of Science ®Google Scholar
• Hafner R, Inderlied CB, Peterson DM et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J. Infect. Dis.180(2), 438–447 (1999).
   PubMed Web of Science ®Google Scholar
• Kemper CA, Meng RC, Nussbaum J et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four drug oral regimen. Rifampicin, ethambutol, clofazimine, and ciprofloxacin. Ann. Intern. Med.116(4), 466–472 (1992).
   PubMed Web of Science ®Google Scholar
• Rolla V, Jacomet C, Salause B et al. Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (dMAC) in a pair matched case–control study. Rev. Inst. Med. Trop. Sao Paulo41(5), 273–277 (1999).
   PubMedGoogle Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Corti M, Villafañe MF, Ambroggi M, Sawicki M, Gancedo E. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy. Rev. Inst. Med. Trop. Sao Paulo49(4), 267–270 (2007).
   PubMedGoogle Scholar
• Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev.5(2), 67–79 (2003).
   PubMedGoogle Scholar
• Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.20(2), 122–128 (1999).
   PubMedGoogle Scholar
• Race EM, Adelson, Mitty J et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet351(9098), 252–255 (1998).
   PubMed Web of Science ®Google Scholar
• Cabie A, Abel S, Brebion A, Desbois N, Sobesky G. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis.17(11), 812–813 (1998).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis.5(6), 361–373 (2005).
   PubMed Web of Science ®Google Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS18(12), 1615–1627 (2004).
   PubMed Web of Science ®Google Scholar
• Kumarasamy N, Chaguturu S, Mayer KH et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis co-infected patients after initiation of generic antiretroviral therapy in India. J. Acquir. Immune Defic. Syndr.37(5), 1574–1576 (2004).
   PubMed Web of Science ®Google Scholar
• Ridell J, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl. Med.5(1), 50 (2007).
   PubMed Web of Science ®Google Scholar
• Reisner B, Gatson A, Woods G. Use of Gen-Probe AccuProbes to identify Mycobacterium avium complex, Mycobacterium tuberculosis complex, Mycobacterium kansasii, and Mycobacterium gordonae directly from BACTEC TB broth cultures. J. Clin. Microbiol.32(12), 2995–2998 (1994).
   PubMed Web of Science ®Google Scholar
• Padilla E, Gonzalez V, Manterola J M et al. Comparative evaluation of the new version of the INNO-LiPA mycobacteria and genotype Mycobacterium assays for identification of Mycobacterium species from MB/BacT liquid cultures artificially inoculated with mycobacterial strains. J. Clin. Microbiol.42(7), 3083–3088 (2004).
   PubMed Web of Science ®Google Scholar
• Gürtler V, Harforf C, Bywater J, Mayall BC. Direct identification of slowly growing Mycobacterium species by analysis of the intergenic 16S–23S rDNA spacer region (ISR) using a GelCompar II database containing sequence based optimization for restriction fragment site polymorphisms (RFLPs) for 12 enzymes. J. Microbiol. Methods64(2), 185–199 (2006).
   PubMed Web of Science ®Google Scholar
• Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J. Clin. Microbiol.41(4), 1447–1453 (2003).
   PubMed Web of Science ®Google Scholar
• Kilby JM, Marques MB, Jaye DL, Tabereaux PB, Reddy VB, Waites KB. The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. Am. J. Med.104(2), 123–128 (1998).
   PubMed Web of Science ®Google Scholar
• Pacios E, Alcalá L, Ruiz-Serrano MJ, de Viedma DJ et al. Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections. Clin. Microbiol. Infect.10(8), 734–737 (2004).
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J. Infect. Chemother.12(4), 195–202 (2006).
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards.Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. NCCLS document M24-A (ISBN 1-56238-500-3), PA, USA (2003).
   Google Scholar
• Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections a systematic review. Int. J. Tuberc. Lung Dis.11(6), 606–611 (2007).
   PubMed Web of Science ®Google Scholar
• Meier A, Heifets L, Wallace RJ Jr et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in clonal population. J. Infect. Dis.174(2), 354–360 (1996).
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am. J. Respir. Crit. Care. Med.153(6), 1766–1772 (1996).
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin. Infect. Dis.23(5), 983–989 (1996).
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Benson CA, Dube MP et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann. Intern. Med.121(12), 905–911 (1994).
   PubMed Web of Science ®Google Scholar
• Cohn DL, Fisher EJ, Peng GT et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin. Infect. Dis.29(1), 125–133 (1999).
   PubMed Web of Science ®Google Scholar
• Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin. Infect. Dis.27(5), 1278–1285 (1998).
   PubMed Web of Science ®Google Scholar
• Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb. Mortal. Wkly Rep.53(RR15), 1–112 (2004).
   PubMedGoogle Scholar
• Kuper JJ, D’Aprile M. Drug–drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin. Pharmacokinet.39(3), 203–214 (2000).
   PubMed Web of Science ®Google Scholar
• Gordin FM, Sullam PM, Shafran SD et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis.28(5), 1080–1085 (1998).
   Web of Science ®Google Scholar
• Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin. Infect. Dis.37(9), 1234–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS11(3), 311–317 (1997).
   PubMed Web of Science ®Google Scholar
• Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of adding clofazimine to combined clarithromycin–ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. Eur. J. Clin. Microbiol. Infect. Dis.18(1), 16–22 (1999).
   PubMed Web of Science ®Google Scholar
• Corti M, Palmero D. Antiretroviral treatment in patients with AIDS and mycobacterial diseases. Medicina (Buenos Aires)65(4), 353–360 (2005).
   PubMed Web of Science ®Google Scholar
• Einarson A, Phillips E, Mawji F et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am. J. Perinatol.15(9), 523–525 (1998).
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr. Pharm. Des.10(26), 3221–3228 (2004).
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Paukovics G, Handley A et al. Interferon-γ therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials5(2), 80–85 (2004).
   PubMed Web of Science ®Google Scholar
• US Public Health Service, Infectious Diseases Society of America, Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Infect. Dis. Obstet. Gynecol.10(1), 3–64 (2002).
   PubMedGoogle Scholar
• Havlir DV, Dube MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N. Engl. J. Med.335(6), 392–398 (2006).
   Google Scholar
• Pierce M, Crampton S, Henry D et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med.335(6), 384–391 (1996).
   PubMed Web of Science ®Google Scholar
• Kirk O, Reiss P, Ubberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann. Intern. Med.137(4), 239–250 (2002).
   PubMed Web of Science ®Google Scholar
• Lange CG, Woolley IJ, Brodt RH. Disseminated Mycobacterium avium–intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? Drugs64(7), 679–692 (2004).
   PubMed Web of Science ®Google Scholar
• Brooks JT, Song R, Hanson DL, Wolfe M, Swerdlow DL; Adult and Adolescent Spectrum of Disease Working Group. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992–2002. Clin. Infect. Dis.41(4), 549–553 (2005).
   PubMed Web of Science ®Google Scholar
• Brooks JT, Song R, Hanson DL, Wolfe M, Swerdlow DL. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992–2002. Clin. Infect. Dis.41(4), 549–553 (2005).
   PubMed Web of Science ®Google Scholar